Release of the 79th newsletter from the Institute

The Institute of Myology teams fully mobilised!

 

Welcome to our 79th newsletter.

 

After these last weeks of confinement, Dr. Vincent Varlet, Secretary General of the Institute of Myology, and Pr. Bertrand Fontaine, Medical and Scientific Director of the Institute of Myology, Head of the service of Neuro-Myology and Director of the Myology Centre for Research UMR 974 wish to send you a specific message.

 

During this period of major health crisis, all our teams (health professionals, researchers, technicians, engineers, support services…) remained very motivated to continuing their research activities and work, as far as possible.

 

Early anticipation allowed us to follow our Business Continuity Plan and maintain everything that was possible to maintain. However, some research work and clinical trials in progress unfortunately had to be stopped. We had to adapt to an unprecedented situation and rethink the way we operate.

 

But, thanks to the commitment of our teams and our responsiveness, we were able to save a certain number of health care and research activities.

 

The practitioners of the service of Neuro-Myology have identified the most fragile neuromuscular patients as a priority in order to continue to offer them the medical care they needed despite the context. We have also chosen to maintain some of our essential research activities and, in particular, specific clinical trials (within a framework of reinforced health security) whose abrupt termination would have resulted in the loss of all the work undertaken for years and would have had dramatic consequences for the patients.

 

We again wish to salute the extraordinary commitment of our staffs of physicians and caregivers – all mobilized – but also of our researchers, technicians and engineers from the Myology Centre for Research, who, despite the risks, volunteered to help the hospital roll back the virus. For example, our teams were urgently requested to provide assistance with the investigation of the CORIMMUNO-19 clinical trial.

 

Today, we must also think about the post confinement and ensure the future of our research and care activities to meet many challenges. We have all prepared for the resumption of our activities in a reduced and gradual way at first, in order to limit risks and losses, but we remain focus on our strategic objectives and do our utmost to pursue the advancement of our initiated projects by pooling our active forces and our resources.

 

Thank you all for reading and supporting us!

 

> Access the 79th newsletter from the Institute